Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors

Diego O. Croci, Juan P. Cerliani, Tomas Dalotto-Moreno, Santiago P. Méndez-Huergo, Ivan D. Mascanfroni, Sebastián Dergan-Dylon, Marta A. Toscano, Julio J. Caramelo, Juan J. García-Vallejo, Jing Ouyang, Enrique A Mesri, Melissa R. Junttila, Carlos Bais, Margaret A. Shipp, Mariana Salatino, Gabriel A. Rabinovich

Research output: Contribution to journalArticle

237 Citations (Scopus)

Abstract

The clinical benefit conferred by vascular endothelial growth factors (VEGF)-targeted therapies is variable, and tumors from treated patients eventually reinitiate growth. Here, we identify a glycosylation-dependent pathway that compensates for the absence of cognate ligand and preserves angiogenesis in response to VEGF blockade. Remodeling of the endothelial cell (EC) surface glycome selectively regulated binding of galectin-1 (Gal1), which upon recognition of complex N-glycans on VEGFR2, activated VEGF-like signaling. Vessels within anti-VEGF-sensitive tumors exhibited high levels of α2-6-linked sialic acid, which prevented Gal1 binding. In contrast, anti-VEGF refractory tumors secreted increased Gal1 and their associated vasculature displayed glycosylation patterns that facilitated Gal1-EC interactions. Interruption of β1-6GlcNAc branching in ECs or silencing of tumor-derived Gal1 converted refractory into anti-VEGF-sensitive tumors, whereas elimination of α2-6-linked sialic acid conferred resistance to anti-VEGF. Disruption of the Gal1-N-glycan axis promoted vascular remodeling, immune cell influx and tumor growth inhibition. Thus, targeting glycosylation-dependent lectin-receptor interactions may increase the efficacy of anti-VEGF treatment. PaperFlick

Original languageEnglish
Pages (from-to)744-758
Number of pages15
JournalCell
Volume156
Issue number4
DOIs
StatePublished - Feb 13 2014

Fingerprint

Vascular Endothelial Growth Factors
Mitogen Receptors
Glycosylation
Galectin 1
Refractory materials
Tumors
Neoplasms
Endothelial cells
N-Acetylneuraminic Acid
Polysaccharides
Endothelial Cells
Growth
Cell Communication
Ligands

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Croci, D. O., Cerliani, J. P., Dalotto-Moreno, T., Méndez-Huergo, S. P., Mascanfroni, I. D., Dergan-Dylon, S., ... Rabinovich, G. A. (2014). Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell, 156(4), 744-758. https://doi.org/10.1016/j.cell.2014.01.043

Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. / Croci, Diego O.; Cerliani, Juan P.; Dalotto-Moreno, Tomas; Méndez-Huergo, Santiago P.; Mascanfroni, Ivan D.; Dergan-Dylon, Sebastián; Toscano, Marta A.; Caramelo, Julio J.; García-Vallejo, Juan J.; Ouyang, Jing; Mesri, Enrique A; Junttila, Melissa R.; Bais, Carlos; Shipp, Margaret A.; Salatino, Mariana; Rabinovich, Gabriel A.

In: Cell, Vol. 156, No. 4, 13.02.2014, p. 744-758.

Research output: Contribution to journalArticle

Croci, DO, Cerliani, JP, Dalotto-Moreno, T, Méndez-Huergo, SP, Mascanfroni, ID, Dergan-Dylon, S, Toscano, MA, Caramelo, JJ, García-Vallejo, JJ, Ouyang, J, Mesri, EA, Junttila, MR, Bais, C, Shipp, MA, Salatino, M & Rabinovich, GA 2014, 'Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors', Cell, vol. 156, no. 4, pp. 744-758. https://doi.org/10.1016/j.cell.2014.01.043
Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014 Feb 13;156(4):744-758. https://doi.org/10.1016/j.cell.2014.01.043
Croci, Diego O. ; Cerliani, Juan P. ; Dalotto-Moreno, Tomas ; Méndez-Huergo, Santiago P. ; Mascanfroni, Ivan D. ; Dergan-Dylon, Sebastián ; Toscano, Marta A. ; Caramelo, Julio J. ; García-Vallejo, Juan J. ; Ouyang, Jing ; Mesri, Enrique A ; Junttila, Melissa R. ; Bais, Carlos ; Shipp, Margaret A. ; Salatino, Mariana ; Rabinovich, Gabriel A. / Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. In: Cell. 2014 ; Vol. 156, No. 4. pp. 744-758.
@article{537d8732b24845fc9343e99c5e2934f6,
title = "Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors",
abstract = "The clinical benefit conferred by vascular endothelial growth factors (VEGF)-targeted therapies is variable, and tumors from treated patients eventually reinitiate growth. Here, we identify a glycosylation-dependent pathway that compensates for the absence of cognate ligand and preserves angiogenesis in response to VEGF blockade. Remodeling of the endothelial cell (EC) surface glycome selectively regulated binding of galectin-1 (Gal1), which upon recognition of complex N-glycans on VEGFR2, activated VEGF-like signaling. Vessels within anti-VEGF-sensitive tumors exhibited high levels of α2-6-linked sialic acid, which prevented Gal1 binding. In contrast, anti-VEGF refractory tumors secreted increased Gal1 and their associated vasculature displayed glycosylation patterns that facilitated Gal1-EC interactions. Interruption of β1-6GlcNAc branching in ECs or silencing of tumor-derived Gal1 converted refractory into anti-VEGF-sensitive tumors, whereas elimination of α2-6-linked sialic acid conferred resistance to anti-VEGF. Disruption of the Gal1-N-glycan axis promoted vascular remodeling, immune cell influx and tumor growth inhibition. Thus, targeting glycosylation-dependent lectin-receptor interactions may increase the efficacy of anti-VEGF treatment. PaperFlick",
author = "Croci, {Diego O.} and Cerliani, {Juan P.} and Tomas Dalotto-Moreno and M{\'e}ndez-Huergo, {Santiago P.} and Mascanfroni, {Ivan D.} and Sebasti{\'a}n Dergan-Dylon and Toscano, {Marta A.} and Caramelo, {Julio J.} and Garc{\'i}a-Vallejo, {Juan J.} and Jing Ouyang and Mesri, {Enrique A} and Junttila, {Melissa R.} and Carlos Bais and Shipp, {Margaret A.} and Mariana Salatino and Rabinovich, {Gabriel A.}",
year = "2014",
month = "2",
day = "13",
doi = "10.1016/j.cell.2014.01.043",
language = "English",
volume = "156",
pages = "744--758",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors

AU - Croci, Diego O.

AU - Cerliani, Juan P.

AU - Dalotto-Moreno, Tomas

AU - Méndez-Huergo, Santiago P.

AU - Mascanfroni, Ivan D.

AU - Dergan-Dylon, Sebastián

AU - Toscano, Marta A.

AU - Caramelo, Julio J.

AU - García-Vallejo, Juan J.

AU - Ouyang, Jing

AU - Mesri, Enrique A

AU - Junttila, Melissa R.

AU - Bais, Carlos

AU - Shipp, Margaret A.

AU - Salatino, Mariana

AU - Rabinovich, Gabriel A.

PY - 2014/2/13

Y1 - 2014/2/13

N2 - The clinical benefit conferred by vascular endothelial growth factors (VEGF)-targeted therapies is variable, and tumors from treated patients eventually reinitiate growth. Here, we identify a glycosylation-dependent pathway that compensates for the absence of cognate ligand and preserves angiogenesis in response to VEGF blockade. Remodeling of the endothelial cell (EC) surface glycome selectively regulated binding of galectin-1 (Gal1), which upon recognition of complex N-glycans on VEGFR2, activated VEGF-like signaling. Vessels within anti-VEGF-sensitive tumors exhibited high levels of α2-6-linked sialic acid, which prevented Gal1 binding. In contrast, anti-VEGF refractory tumors secreted increased Gal1 and their associated vasculature displayed glycosylation patterns that facilitated Gal1-EC interactions. Interruption of β1-6GlcNAc branching in ECs or silencing of tumor-derived Gal1 converted refractory into anti-VEGF-sensitive tumors, whereas elimination of α2-6-linked sialic acid conferred resistance to anti-VEGF. Disruption of the Gal1-N-glycan axis promoted vascular remodeling, immune cell influx and tumor growth inhibition. Thus, targeting glycosylation-dependent lectin-receptor interactions may increase the efficacy of anti-VEGF treatment. PaperFlick

AB - The clinical benefit conferred by vascular endothelial growth factors (VEGF)-targeted therapies is variable, and tumors from treated patients eventually reinitiate growth. Here, we identify a glycosylation-dependent pathway that compensates for the absence of cognate ligand and preserves angiogenesis in response to VEGF blockade. Remodeling of the endothelial cell (EC) surface glycome selectively regulated binding of galectin-1 (Gal1), which upon recognition of complex N-glycans on VEGFR2, activated VEGF-like signaling. Vessels within anti-VEGF-sensitive tumors exhibited high levels of α2-6-linked sialic acid, which prevented Gal1 binding. In contrast, anti-VEGF refractory tumors secreted increased Gal1 and their associated vasculature displayed glycosylation patterns that facilitated Gal1-EC interactions. Interruption of β1-6GlcNAc branching in ECs or silencing of tumor-derived Gal1 converted refractory into anti-VEGF-sensitive tumors, whereas elimination of α2-6-linked sialic acid conferred resistance to anti-VEGF. Disruption of the Gal1-N-glycan axis promoted vascular remodeling, immune cell influx and tumor growth inhibition. Thus, targeting glycosylation-dependent lectin-receptor interactions may increase the efficacy of anti-VEGF treatment. PaperFlick

UR - http://www.scopus.com/inward/record.url?scp=84894136530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894136530&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2014.01.043

DO - 10.1016/j.cell.2014.01.043

M3 - Article

VL - 156

SP - 744

EP - 758

JO - Cell

JF - Cell

SN - 0092-8674

IS - 4

ER -